• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc. (Amendment)

    2/14/24 2:06:57 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGIO alert in real time by email
    SC 13G/A 1 rocksprings-agio123123a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    AGIOS PHARMACEUTICALS, INC.

    (Name of Issuer)

     

    Common Stock, Par Value $0.001 per share

    (Title of Class of Securities)

     

    00847X104

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  00847X104
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Management LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,152,173
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,152,173
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,152,173
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    3.85%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     


     

    CUSIP No.  00847X104
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,152,173
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,152,173
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,152,173
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    3.85%
    12
    TYPE OF REPORTING PERSON
     
    OO; HC

     

     
     

     

    CUSIP No.  00847X104
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    AGIOS PHARMACEUTICALS, INC. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices

    88 Sidney Street

    Cambridge, MA 02139

    Item 2.(a) Name of Person Filing

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    i. Rock Springs Capital Management LP (“RSCM”);

    ii. Rock Springs Capital LLC (“RSC”)

    This Statement relates to Shares (as defined herein) held directly by Rock Springs Capital Master Fund LP (“Master Fund”), which is a Cayman Island exempted limited partnership, and Four Pines Master Fund LP (“Four Pines”), which is a Cayman Islands exempted limited partnership, and indirectly held by RSCM, a Delaware limited partnership, and RSC, a Delaware limited liability company. RSCM serves as the investment manager to each of the Master Fund and Four Pines. RSC is the general partner of RSCM.

    (b) Address of Principal Business Office, or, if none, Residence

    Rock Springs Capital Management LP and Rock Springs Capital LLC

    650 South Exeter, Suite 1070

    Baltimore, MD 21202

     

     

    (c) Citizenship

    Rock Springs Capital Management LP - Delaware

    Rock Springs Capital LLC - Delaware

     (d) Title of Class of Securities

    Common Stock, Par Value $0.001 per share (the “Shares”)

     (e) CUSIP No.:

    00847X104

     
     

     

    CUSIP No.  00847X104
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 00847X104
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    As of the date of this filing, the Reporting Persons may be deemed to be the beneficial owners of 2,152,173 Shares, which amount includes 1,900,000 Shares directly beneficially owned by the Master Fund, and 252,173 Shares directly beneficially owned by Four Pines. The percent of class is determined by dividing the number of Shares beneficially owned by the Reporting Persons by 55,891,284 as reported on the Issuer’s Form 10-Q filed on November 2, 2023.

    (a) Amount beneficially owned:

    Rock Springs Capital Management LP: 2,151,814

    Rock Springs Capital LLC: 2,151,814

     

    (b) Percent of class:

    Rock Springs Capital Management LP: 3.85%

    Rock Springs Capital LLC: 3.85%

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

     

    (ii) Shared power to vote or to direct the vote:

    Rock Springs Capital Management LP: 2,151,814

    Rock Springs Capital LLC: 2,151,814

     

    (iii) Sole power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

     

    (iv) Shared power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 2,151,814

    Rock Springs Capital LLC: 2,151,814

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Please see response to Item 2.

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than the activities solely in connection with a nomination under §240.14a-11.

     

     

     
     
    CUSIP No.  20454B104
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

       

     

     

     
     
    CUSIP No. 20454B104
     SCHEDULE 13G
    Page 8 of 8 Pages

     

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Date: February 14, 2024

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

     

     

     

     

     

     

     

    Get the next $AGIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGIO

    DatePrice TargetRatingAnalyst
    2/24/2025$58.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    10/10/2024$51.00Outperform
    Raymond James
    9/27/2024$60.00 → $56.00Outperform → Market Perform
    Leerink Partners
    2/8/2024Overweight
    Cantor Fitzgerald
    2/3/2023$41.00Overweight
    Piper Sandler
    11/17/2022$17.00 → $32.00Sell → Neutral
    Goldman
    7/27/2022$33.00Mkt Perform → Outperform
    SVB Leerink
    More analyst ratings

    $AGIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

      CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is dedicated to devel

      5/9/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

      CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is dedicated to dev

      5/2/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kin

      5/1/25 6:30:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Agios Pharma with a new price target

      H.C. Wainwright initiated coverage of Agios Pharma with a rating of Buy and set a new price target of $58.00

      2/24/25 7:01:42 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Agios Pharma

      Scotiabank initiated coverage of Agios Pharma with a rating of Sector Outperform

      10/16/24 8:38:23 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on Agios Pharma with a new price target

      Raymond James resumed coverage of Agios Pharma with a rating of Outperform and set a new price target of $51.00

      10/10/24 8:30:27 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PYRUKYND issued to AGIOS PHARMACEUTICALS INC

      Submission status for AGIOS PHARMACEUTICALS INC's drug PYRUKYND (ORIG-1) with active ingredient MITAPIVAT has changed to 'Approval' on 02/17/2022. Application Category: NDA, Application Number: 216196, Application Classification: Type 1 - New Molecular Entity

      2/17/22 2:39:08 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for TIBSOVO issued to AGIOS PHARMS INC

      Submission status for AGIOS PHARMS INC's drug TIBSOVO (SUPPL-7) with active ingredient IVOSIDENIB has changed to 'Approval' on 03/18/2021. Application Category: NDA, Application Number: 211192, Application Classification: Labeling

      3/22/21 5:06:31 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      11/14/24 3:44:53 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      11/8/24 2:40:47 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      2/14/24 2:21:13 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fouse Jacqualyn A converted options into 15,933 shares and sold $194,172 worth of shares (7,497 units at $25.90), increasing direct ownership by 6% to 149,220 units (SEC Form 4)

      4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      4/10/25 4:02:58 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Corp Dev & Strategy Viswanadhan Krishnan

      4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      3/7/25 4:18:52 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Viswanadhan Krishnan

      3 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      3/7/25 4:15:46 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development as Chief Business Officer of Agios Pharmaceuticals (NASDAQ:AGIO), and previously held strategic product and portfolio roles at Biogen (NASDAQ:BIIB). In her role at Cardurion, she will be responsible for leading corporate development, bus

      1/8/25 8:00:00 AM ET
      $AGIO
      $BIIB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Agios Appoints Catherine Owen to Board of Directors

      – John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Catherine Owen has been appointed to its board of directors, effective June 13, 2023. Agios also announced that, following a collaborative succession planning process, John Maraganore, Ph.D., who has served as a valuable board member and advisor to the company since 2011, will step down from the board of directors, effective immediately, and

      5/25/23 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Appoints Jeffrey Capello to Board of Directors

      – Board Member Paul Clancy Will Step Down at the End of His Term – CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Jeffrey Capello has been appointed to its board of directors. Agios also announced that Paul Clancy will step down from the board of directors at the end of his term, effective June 13, 2023. "Agios is dedicated to cultivating a diverse board that is focused on the company's long-term value creation for patients and shareholders. As such, we are thrilled to welcome Jeff, whose nearly 30-year track record of driving profitab

      4/19/23 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Agios Pharmaceuticals Inc.

      10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      5/1/25 10:26:14 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      5/1/25 6:32:25 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Agios Pharmaceuticals Inc.

      DEFA14A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      4/25/25 4:05:10 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Financials

    Live finance-specific insights

    See more
    • Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kin

      5/1/25 6:30:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

      CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET to report its first quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company's website approximately two hours after the event. About AgiosAgios is the pioneering leader in PK act

      4/17/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      – Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 – – Completed Enrollment for Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Results Expected in Late 2025, with Potential U.S. Commercial Launch in 2026 – – Early- and Mid-Stage Pipeline Offers Strong Foundation for Innovation and Growth – – PYRUKYND Net Revenue of $10.7 Million in Q4; Cash, Cash Equivalents and Marketable Securitie

      2/13/25 6:31:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care